BioSpace News Archive

This discussion features DEIB leaders from California Life Sciences, MassBio, Eli Lilly and Takeda. We explore changing attitudes in the life sciences workforce, if organizations are adjusting either their DEIB or communication strategies, and how evolving philosophies around DEIB are impacting human resources and talent acquisition activities.

On this episode of Denatured, Lori Ellis and guests discuss President Biden’s Executive Order on Advancing Women’s Health Research and Innovation and the outlook of investment in women’s health.

Pfizer’s investigational Duchenne muscular dystrophy gene therapy fordadistrogene movaparvovec has been hit with another patient death, forcing the pharma to pause dosing in its Phase III study.

Olema Pharmaceuticals, Inc. announced that it will present new clinical data from the Company’s ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib in a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Annual Congress 2024 taking place May 15-17, 2023, in Berlin, Germany.

Amicus Therapeutics announced that management will participate in a fireside chat at the Bank of America 2024 Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024, at 1:40 p.m. P.T.

Akero Therapeutics, Inc. announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV.

EyePoint Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments.

Chemomab Therapeutics Ltd. announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market notifying the Company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain compliance with Nasdaq’s minimum $1.00 bid price per share requirement.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease, a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain, an ocular condition associated with pain but without an FDA approved therapy, announced upcoming presentations at two investor conferences in May 2024.

TETROUS, INC., a leading regenerative medicine company announced that it has completed the first surgical cases using EnFix TAC™, its latest product that expands its line of EnFix™ implants to cover every surgical technique for rotator cuff repair.